-
Launch of Pitavastatin tablets in the United States – Sawai’s First generic ANDA approval and launch for US market under Paragraph IV–
-
Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP
-
Upsher-Smith Expands Vigadrone® (vigabatrin) Franchise to Include Tablets
-
Upsher-Smith Launches Isotretinoin Capsules, USP
-
Upsher-Smith Completes Sale of Two Migraine Products
-
Upsher-Smith Divests Two Migraine Products
-
Sawai Announces Listing of Two Generic Drugs with Eight Strengths
-
Upsher-Smith Adds Dicyclomine Hydrochloride Capsules, USP to its Product Line
-
Sawai Group Holdings Announces Change of Representative Directors and Corporate Officers
-
Upsher-Smith Expands Ophthalmic Portfolio with Launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
-
Upsher-Smith Launches Fluphenazine Hydrochloride Tablets
-
Upsher-Smith Launches Dicyclomine Hydrochloride Tablets
-
Sawai Receives Approvals for Three Generic Drugs with 10 Strengths
-
Upsher-Smith Expands Fluoxetine Product Line to Include an Oral Solution
-
Sawai Announces Listing of Six Generic Drugs with 12 Strengths
-
Sawai Receives Approvals for Six Generic Drugs with 13 Strengths
-
Sawai Announces Listing of Five Generic Drugs with 11 Strengths
-
Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths
-
Sawai Announces Listing of Five Generic Drugs with Nine Strengths
-
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
